Our global Antitrust Healthcare & Life Sciences practice supports clients across merger control, foreign direct investment, antitrust litigation, investigations and compliance. Our team includes former regulators from leading agencies worldwide, alongside colleagues with decades of experience advising businesses in pharmaceuticals, medical devices, hospital systems, healthcare technology and wellness. We have deep experience in contentious and non‑contentious matters, including high‑profile antitrust challenges and complex multi‑jurisdictional transactions across major global markets. Our clients value that we stay ahead of developments affecting the healthcare and life sciences sector and work closely with them to navigate change and strengthen their business operations.

We are a top-tier global powerhouse for dispute resolution, including litigation, international arbitration and investigations, in healthcare and life sciences, with one of the strongest benches in the world and fully integrated teams across the US, Europe and APAC. We combine deep sector knowledge with a strategic, commercially focused approach, representing clients in complex class actions and mass litigation, including consumer claims, data misuse, antitrust and IP disputes, and ESG‑related actions. We advise on product liability across design, manufacturing, recalls, safety investigations and emerging AI risks. Alongside bet-the company trials, arbitration proceedings and other court actions, we help clients anticipate and resolve disputes early, protecting commercial objectives while avoiding escalation. Our experience across cutting‑edge science, regulation and litigation enables us to guide clients through fast‑evolving global risk landscapes.

Clifford Chance helps healthcare and life sciences clients protect, defend and maximise the value of their IP.

We advise on IP strategies that protect scientific advances, support product pipelines and enable commercialisation. We help clients align patent, data and brand protection with regulatory and market goals.

Our experience includes patent litigation before the Unified Patent Court and national courts. We advise on disputes involving pharmaceuticals, biologics, diagnostics, medical devices, cell and gene therapies.

As AI reshapes R&D, clinical development and digital health, we help clients manage related IP issues. These include AI-generated inventions, data use, model training and infringement risk.

We also support global branding, trademark protection, enforcement and portfolio management.

TBA

TBA

TBA